new_0222_0379|GLUE|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0379|GLUE|1|Monte Rosa Therapeutics Inc Total Current Assets (Quarterly) (USD)|Monte Rosa Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Monte Rosa Therapeutics Inc Inventories (Quarterly) (USD)|Monte Rosa Therapeutics Inc Net PP&E (Quarterly) (USD)|Monte Rosa Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Monte Rosa Therapeutics Inc Total Liabilities (Quarterly) (USD)|Monte Rosa Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Monte Rosa Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Monte Rosa Therapeutics Inc Total Deposits (Quarterly) (USD)|Monte Rosa Therapeutics Inc Book Value (Quarterly) (USD)|Monte Rosa Therapeutics Inc Retained Earnings (Quarterly) (USD)|Monte Rosa Therapeutics Inc Treasury Stock (Quarterly) (USD)|Monte Rosa Therapeutics Inc EV to Revenues|Monte Rosa Therapeutics Inc EV to Earnings|Monte Rosa Therapeutics Inc EV to Free Cash Flow|Monte Rosa Therapeutics Inc EV to Assets (Quarterly)|Monte Rosa Therapeutics Inc PS Ratio|Monte Rosa Therapeutics Inc PE Ratio|Monte Rosa Therapeutics Inc Price to Book Value|Monte Rosa Therapeutics Inc PEG Ratio|Monte Rosa Therapeutics Inc Debt to Equity Ratio|Monte Rosa Therapeutics Inc Dividend Yield|Monte Rosa Therapeutics Inc Shareholder Yield (TTM)|Monte Rosa Therapeutics Inc Percent of Shares Outstanding Short|Monte Rosa Therapeutics Inc Total Receivables (Quarterly) (USD)|Monte Rosa Therapeutics Inc Total Payables (Quarterly) (USD)|Monte Rosa Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Monte Rosa Therapeutics Inc Return on Invested Capital|Monte Rosa Therapeutics Inc Quality Ratio Score|Monte Rosa Therapeutics Inc Momentum Score|Monte Rosa Therapeutics Inc Beta (1Y)|Monte Rosa Therapeutics Inc Sustainable Growth Rate (TTM)|Monte Rosa Therapeutics Inc Institutional Investor Ownership Percentage|Monte Rosa Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Monte Rosa Therapeutics Inc Total Employees (Annual)|Monte Rosa Therapeutics Inc EPS Diluted (Quarterly) (USD)|Monte Rosa Therapeutics Inc Shares Outstanding|Monte Rosa Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Monte Rosa Therapeutics Inc Ordinary Shares Number (Quarterly)|Monte Rosa Therapeutics Inc Payout Ratio|Monte Rosa Therapeutics Inc Quick Ratio (Quarterly)|Monte Rosa Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Monte Rosa Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Monte Rosa Therapeutics Inc Effective Tax Rate (TTM)|Monte Rosa Therapeutics Inc Return on Equity|Monte Rosa Therapeutics Inc Net Income (TTM) (USD)|Monte Rosa Therapeutics Inc Revenue (TTM) (USD)|Monte Rosa Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Monte Rosa Therapeutics Inc Revenue (Quarterly) (USD)|Monte Rosa Therapeutics Inc Gross Profit (Quarterly) (USD)|Monte Rosa Therapeutics Inc SG&A Expense (Quarterly) (USD)|Monte Rosa Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Monte Rosa Therapeutics Inc Net Income (Quarterly) (USD)|Monte Rosa Therapeutics Inc Net Interest Income (Quarterly) (USD)|Monte Rosa Therapeutics Inc Price (USD)|Monte Rosa Therapeutics Inc Total Return Price (USD)|Monte Rosa Therapeutics Inc Enterprise Value (USD)|Monte Rosa Therapeutics Inc 30-Day Average Daily Volume|Monte Rosa Therapeutics Inc 1 Year Price Returns (Daily)||
new_0222_0379|GLUE|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0379|GLUE|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly||
new_0222_0379|GLUE|5|91|91||91||91|91|91||91|91||||1.44242424242||||1.43827160494|||1.44242424242||15.3571428571||91|91|||||||91.3333333333|50.5|91.3333333333|23.5||91|||91.3333333333|91.4|||91|||||91.3333333333|91.3333333333|91.3333333333|91.3333333333|1.43975903614|1.43975903614|1.44242424242|1.44117647059|||
new_0222_0379|GLUE|6|3|3||3||3|3|3||3|3||||165||||162|||165||14||3|3|||||||6|2|6|6||3|||6|5|||3|||||6|6|6|6|166|166|165|136|||
new_0222_0379|GLUE|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0379|GLUE|202003||||||||||||||||||||||||||||||||||21.7378||-0.1979||||||-0.1976|||||||||0.478|-4.302|-4.302|-0.003|||||||
new_0222_0379|GLUE|202006||||||||||||||||||||||||||||||||||21.7378||-0.2468||||||-0.2482|||||||||0.541|-5.364|-5.364|0.001|||||||
new_0222_0379|GLUE|202009||||||||||||||||||||||||||||||||||21.7378||-0.3017||||||-0.2937|||||||||0.914|-6.558|-6.558|0.002|||||||
new_0222_0379|GLUE|202012|43.591|41.699||4.623||98.106|29.275|68.831||-48.728|-48.077|||||||||||||||7.066|0.001|||||||21.7378||-0.9042|||42.5402|||-0.902||||-35.88|||||2.073|-19.656|-19.656|0.009|||||||
new_0222_0379|GLUE|202103|171.707|168.436||7.732||241.219|9.091|232.128||-60.616|-60.353|||||||||||||||7.326|0.001|||||||21.7378||-0.56|||42.5402|||-0.5684||||-43.854|||||2.231|-12.276|-12.276|0.006|||||||
new_0222_0379|GLUE|202106|358.289|357.06||8.923||12.263|10.791|1.472||356.678|-78.758||||-13.1362||||2.8387|||||1.6531||7.463|0.004|||||||5.0706|83|-3.63|44.6037||44.6037|||-3.5716|-206.739|||-56.895|||||3.486|-18.405|-18.405|0.014|22.7|22.7|655.444|180085.7667||24.52|35.69
new_0222_0379|GLUE|202109|370.519|367.034||11.801||14.744|12.743|2.001||369.305|-98.595||||-10.8501||||2.8044|||||5.4342||3.53|0.005|||||||45.9879|94|-0.43|46.4839||46.4839|||-0.4304|-31.011|||-70.174|||||4.753|-19.837|-19.837|0.013|22.28|22.28|668.6273|277197.6667||23.45|19.39
new_0222_0379|GLUE|202112|||||||||||||||-9.4544||||2.5715|||||7.1817|||||||||||||||||||||||||||||||20.42|20.42|582.6165|168641.8667||12.66|13.15